JNJ reports negative Topamax data

The R.W. Johnson Pharmaceutical Research Institute, a JNJ subsidiary, said its Topamax topiramate missed the primary efficacy endpoint in three pivotal studies of patients with diabetic neuropathy. As a result, the company said it will not pursue the indication for diabetic neuropathic pain and it will discontinue the open-label extension of these trials. The remaining trial of topiramate, which is being conducted by JNJ company Ortho-McNeil Pharmaceutical has a different design and will be completed, JNJ said. ...